DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* TC LAND EXPRESSION *


 

2002 - Bretagne
Nantes
www.tcland-expression.com

 

Design, Diagnostics
Key words: Biomarkers, Transplantation, Auto-immune diseases
Mission: to develop gene expression biomarkers in transplantation and immunology through proprietary strategy of personalized medicine
Clients: Pharmaceutical industry, Research labs
contact@tcland-biotech.com

Age: 14 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Tchelingerian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder), Diatos (CEO)]
Sc.Dir.-CSO: Guillet (Marina) [born 1973, Ph.D., ex-TcLand (CEO)]
Clin.Dir.-CMO: Larcier (Patrick) [Pharm.D., MBA Essec, ex-Neovacs, Biogen-Idec, Quintiles, Parexel, GSK]
Fin.Dir.-CFO: Jaffré (Philippe) [MBA, ex-Novartis, Chiron, Dana Capital]
SalesMktg: Kazek (Elodie) [Pharm.D., ESSEC, ex-BioMerieux, Fresenius Kabi, Merck KgAa]
BusDev: Payne (Peter) [Ms. pharmacology, ex-Quintiles, Wellcome, Sterling Drug, Glaxo], also Head of US-Business
Financers (Hist.): Auriga Partners, Debiopharm, Genzyme Ventures, Quest For Growth, Beviguen
Note: the previous URL, tcland-biotech.com, has been replaced by tcland-expression.com, late 2010

Turnover (M€) : 0.42 (2009), 0.2 (2008), 0.06 (2007), 0.13 (2006)
Total funding (M€) : 9.0
Last funding (M€) : 8.2
Focus : Multiple
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .05 Nomination : John Tchelingerian, as Chairman and CEO [ex-Diatos] ORGN [9 years]
2011 .06 Financing (no interest loan) : 1.2 M€, by OSEO and ERDF to support a leading project in personalised medicine focused on rheumatoid arthritis DEBT [8 years]
2011 .03 Partnering research agreement within the Innovative Medicines Initiative (IMI) Be The CURE, the largest European consortium for Rheumatology R&D [8 years]
2010 .07 Partnering research agreement with Inserm Transfert, on the development of companion diagnostic tests for rheumatoid arthritis therapies R&D [7 years]
2010 .05 Financing (no interest loan) : 0.45 M€ from ANR for diagnostic program in rheumatoid arthritis DEBT [7 years]
2009 .10 Clinical trial for validation study on K-RejX diagnostic blood test in identification of kidney transplant recipients at risk of chronic rejection (beginning) CLIN [7 years]
2009 .09 Round financing : 1.0 M€ through Tepa law (plus 2.2 M€ as no interest loan from ANR for Tolestim development), to Tc Land Pharma RFIN [6 years]
2009 .04 Financing (no interest loan) : 1.8 M€ from OSEO for innovation support DEBT [6 years]
2008 .08 Licensing-in of a liver biomarker (worldwide rights) from Idibaps (Spain) LICIN [5 years]
2008 .01 Set-up of CIMNA, an integrated immuno-monitoring service platform, located in Nantes ORGC [5 years]
2007 .12 1st round-financing : 8.2 M€, led by Auriga Partners RFINA [5 years]
2007 .12 Company split into 2 autonomous units : TcLand Expression (previously TcLand) and TcLand Pharma, focused on the development of therapeutic molecules ORG [5 years]
2006 .00 Nomination : Alain Huriez, as Chairman and CEO [ex-Neovacs CEO, 2003-2006] ORGN [3 years]
2006 .06 Licensing-out to Debiopharm with capital sharing LICOUT [3 years]
2005 .06 Seed financing : undisclosed M€, by Inserm-Transfert SFIN [2 years]
2002 .10 Company founded by Marina Guillet, Alain Huriez, as a spin-off of Itert ORGF [0 year]

Actualisation / Updating: 27-Dec-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende